RE:RE:RE:Viacycte reports positive results from studyThat's true another example of a likely failure hidden behind a vague description of results. Sigilon is also pretty much out of the picture. Vertex at least has some decent 90 day data on the first patient but from my understanding they are just injecting into the portal vein with immunosuppression and are way behind anyways. "Day 90, HbA1c improved from 8.6% at baseline to 7.2%" nothing to write home about although they did see a large decrease (91%) in daily exogenous insulin use but this just shows their cells work. How will they overcome the limitations of injecting into the portal vein. Sernova could be the solution.
It's too bad Sernova isn't strong in business because they are in a position where it could certainly be leveraged. I have hope Philip vindicates himself or at least between him and Hollar they can peg something down that investors can be happy with.